;
Skip to main content
Home > Week in Review > Clinical Status

Chronological Index of : Clinical Status

 Current Issue
  • IBI-10090: Phase III ongoing

    Icon Bioscience Inc., Sunnyvale, Calif. Product: IBI-10090 Business: Ophthalmic Molecular target: NA Description: Sustained-release formulation of anti-inflammatory agent dexamethasone delivered using Verisome …

    Published on 10/13/2014
  • Masican masitinib: Phase III ongoing

    AB Science S.A. (Euronext:AB), Paris, France Product: Masican masitinib (AB1010) Business: Dermatology Molecular target: Stem cell factor (SCF) receptor tyrosine kinase (c-Kit) (KIT) (CD117) Description: Stem cell …

    Published on 10/13/2014
  • MiR-21: Clinical trial started

    Regulus Therapeutics Inc. (NASDAQ:RGLS), San Diego, Calif. Product: MiR-21 (anti-miR-21) (RG-012) (formerly antagomir-21) Business: Renal Molecular target: MicroRNA-21 (miR-21) Description: Antisense oligonucleotide …

    Published on 10/13/2014
  • NBI-98854: Phase Ib started

    Neurocrine Biosciences Inc. (NASDAQ:NBIX), San Diego, Calif. Product: NBI-98854 Business: Neurology Molecular target: Vesicular monoamine transporter 2 (VMAT2) (SLC18A2) Description: Selective vesicular monoamine …

    Published on 10/13/2014
  • RTA 408: Phase II start

    Reata Pharmaceuticals Inc., Irving, Texas Product: RTA 408 Business: Endocrine/Metabolic Molecular target: Nuclear factor (erythroid-derived 2)-like 2 (NFE2L2) (NRF2); NF-kappa B (NF-kB) Description: Oleanane …

    Published on 10/13/2014
  • RTA 408: Phase II start

    Reata Pharmaceuticals Inc., Irving, Texas Product: RTA 408 Business: Neurology Molecular target: Nuclear factor (erythroid-derived 2)-like 2 (NFE2L2) (NRF2); NF-kappa B (NF-kB) Description: Oleanane triterpenoid that …

    Published on 10/13/2014
  • Simdax levosimendan: Phase III started

    Orion Corp. (HSE:ORNAV; HSE:ORNBV), Espoo, Finland Tenax Therapeutics Inc. (NASDAQ:TENX), Morrisville, N.C. Product: Simdax levosimendan Business: Cardiovascular Molecular target: Potassium channel Description: Calcium …

    Published on 10/13/2014
  • Subcutaneous beloranib: Completed Phase IIa enrollment

    Zafgen Inc. (NASDAQ:ZFGN), Cambridge, Mass. Chong Kun Dang Pharmaceutical Corp. (KSE:001630), Seoul, South Korea Product: Subcutaneous beloranib (ZGN-440, CKD-732) Business: Endocrine/Metabolic Molecular target: …

    Published on 10/13/2014
  • TD139: Phase I/IIa started

    Galecto Biotech AB, Copenhagen, Denmark Product: TD139 Business: Pulmonary Molecular target: Galectin-3 (LGALS3) Description: Galectin-3 (LGALS3) inhibitor Indication: Treat idiopathic pulmonary fibrosis (IPF) Endpoint:…

    Published on 10/13/2014
  • AKB-6548: Phase II started

    Akebia Therapeutics Inc. (NASDAQ:AKBA), Cambridge, Mass. Product: AKB-6548 Business: Hematology Molecular target: Hypoxia-inducible factor prolyl hydroxylase (HIF-PH) (EGLN) Description: Oral hypoxia-inducible factor …

    Published on 10/6/2014
  • Arhalofenate: Completed Phase IIb enrollment

    CymaBay Therapeutics Inc. (NASDAQ:CBAY), Newark, Calif. Product: Arhalofenate (MBX-102) Business: Endocrine/Metabolic Molecular target: Solute carrier family 22 organic anion urate transporter member 12 (SLC22A12) (…

    Published on 10/6/2014
  • Benzhydrocodone/acetaminophen: Clinical trial started

    KemPharm Inc., Coralville, Iowa Product: Benzhydrocodone/acetaminophen (KP201) Business: Neurology Molecular target: NA Description: Abuse-deterrent formulation of benzhydrocodone, a hydrocodone prodrug, and …

    Published on 10/6/2014
  • Benzhydrocodone/acetaminophen: Clinical trial started

    KemPharm Inc., Coralville, Iowa Product: Benzhydrocodone/acetaminophen (KP201) Business: Neurology Molecular target: NA Description: Abuse-deterrent formulation of benzhydrocodone, a hydrocodone prodrug, and …

    Published on 10/6/2014
  • BJI InoPlex: Pivotal trial completed enrollment

    Diaxonhit (Euronext:ALEHT), Paris, France Product: BJI InoPlex Business: Diagnostic Molecular target: NA Description: Non-invasive multi-parameter serologic test Indication: Diagnose articular prosthesis infections …

    Published on 10/6/2014
  • CDX-301: Pilot trial started

    Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Celldex Therapeutics Inc. (NASDAQ:CLDX), Needham, Mass. Product: CDX-301 Business: Transplant Molecular target: FMS-like tyrosine kinase 3 ligand (FLT3LG) Description: FMS…

    Published on 10/6/2014
  • Clotbust ER: Phase III ongoing

    Cerevast Therapeutics Inc., Redmond, Wash. Product: Clotbust ER Business: Neurology Molecular target: NA Description: Headframe that non-invasively delivers therapeutic ultrasound energy to the region of vessel …

    Published on 10/6/2014
  • Drisapersen: Phase II restarted

    Prosensa Holding N.V. (NASDAQ:RNA), Leiden, the Netherlands Product: Drisapersen (2402968) (PRO051, GSK2402968) Business: Musculoskeletal Molecular target: NA Description: Antisense oligoribonucleotide that induces exon…

    Published on 10/6/2014
  • Drisapersen: Phase III restarted

    Prosensa Holding N.V. (NASDAQ:RNA), Leiden, the Netherlands Product: Drisapersen (2402968) (PRO051, GSK2402968) Business: Musculoskeletal Molecular target: NA Description: Antisense oligoribonucleotide that induces exon…

    Published on 10/6/2014
  • Fluticasone propionate/salmeterol xinafoate: Phase III start

    Mylan Inc. (NASDAQ:MYL), Canonsburg, Pa. Pfizer Inc. (NYSE:PFE), New York, N.Y. Product: Fluticasone propionate/salmeterol xinafoate (MGR001) Business: Inflammation Molecular target: Adrenergic receptor beta 2 (ADRB2); …

    Published on 10/6/2014
  • INO-3106: Phase I started

    Inovio Pharmaceuticals Inc. (NASDAQ:INO), Blue Bell, Pa. Product: INO-3106 Business: Cancer Molecular target: NA Description: HPV type 6 immunotherapy Indication: Treat HPV type 6-associated aerodigestive malignances …

    Published on 10/6/2014
  • Lirilumab: Phase II ongoing

    Innate Pharma S.A. (Euronext:IPH), Marseille, France Ono Pharmaceutical Co. Ltd. (Tokyo:4528), Osaka, Japan Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Product: Lirilumab (BMS-986015, IPH2102) Business: Cancer …

    Published on 10/6/2014
  • LymPro Test: Pilot trial completed enrollment

    Amarantus BioScience Holdings Inc. (OTCQB:AMBS), San Francisco, Calif. Memory Dx LLC, Phoenix, Ariz. Product: LymPro Test Business: Diagnostic Molecular target: Not applicable Description: Measure CD69 presentations at …

    Published on 10/6/2014
  • MiStat ELISA: Pilot trial started

    Minomic International Ltd., Macquarie Park, Australia Product: MiStat ELISA Business: Cancer Molecular target: NA Description: Test to detect proprietary biomarker MIL-38 antigen, which is present on prostate cancer …

    Published on 10/6/2014
  • Parsortix cancer cell separation system: Pilot trial started

    Angle plc (LSE:AGL), Guildford, U.K. Product: Parsortix cancer cell separation system Business: Diagnostic Molecular target: NA Description: Microscale device that separates cells on the basis of size and/or surface …

    Published on 10/6/2014
  • Riona ferric citrate: Phase III started

    Keryx Biopharmaceuticals Inc. (NASDAQ:KERX), New York, N.Y. Panion & BF Biotech Inc. (Taiwan:1760), Taipei, Taiwan Japan Tobacco Inc. (Tokyo:2914), Tokyo, Japan Torii Pharmaceutical Co. Ltd. (Tokyo:4551), Tokyo, Japan …

    Published on 10/6/2014

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993